Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal

被引：2
|
作者：
Usmani, S. Z. [1 ]
Hoering, A. [2 ]
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[2] Canc Res & Biostat, Seattle, WA USA
来源：
LEUKEMIA | 2013年 / 27卷 / 12期
关键词：
TOTAL THERAPY 3; MULTIPLE-MYELOMA; BORTEZOMIB; DELETION;
D O I：
10.1038/leu.2013.161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2269 / 2271
页数：3
相关论文
共 50 条
  • [21] Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma
    Lonial, Sagar
    Niesvizky, Ruben
    McCulloch, Leanne
    Rajangam, Kanya
    Vij, Ravi
    [J]. BLOOD, 2012, 120 (21)
  • [22] Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
    Prince, H. Miles
    Adena, Michael
    Smith, Dell Kingsford
    Hertel, Judy
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (02) : 93 - 99
  • [23] Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Richardson, Paul
    Jagannath, Sundar
    Hussein, Mohamad
    Berenson, James
    Singhal, Seema
    Irwin, David
    Williams, Stephanie F.
    Bensinger, William
    Badros, Ashraf Z.
    Vescio, Robert
    Kenvin, Laurie
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome
    Knight, Robert
    Anderson, Kenneth C.
    [J]. BLOOD, 2009, 114 (04) : 772 - 778
  • [24] Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
    Witzig, Thomas E.
    Vose, Julie
    Zinzani, Pier Luigi
    Habermann, Thomas Matthew
    Tuscano, Joseph M.
    Sinha, Rajni
    Williams, Michael E.
    Drach, Johannes W.
    Ramchandren, Rod
    Besisik, Sevgi Kalayoglu
    Zhang, Lei
    Cicero, Sherri
    Fu, Tommy
    Goy, Andre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] A phase II study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (RRMM)
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Jakubowiak, A. J.
    Lonial, S.
    Trudel, S.
    Kukreti, V.
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F. J.
    Somlo, G.
    Zonder, J.
    Song, K.
    Stewart, A. K.
    Stadtmauer, E.
    Kunkel, L.
    Wear, S. Sandra
    Wong, A.
    Orlowski, R. Z.
    Jagannath, S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 7 - 7
  • [26] Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma
    Vij, Ravi
    Wang, Michael
    Jagannath, Sundar
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    Kavalerchik, Edward
    Huang, Mei
    Siegel, David S.
    [J]. BLOOD, 2013, 122 (21)
  • [27] NURSING IMPLICATIONS FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA RECEIVING SINGLE AGENT CARFILZOMIB (KYPROLIS™)
    Catamero, Donna
    [J]. ONCOLOGY NURSING FORUM, 2013, 40 (03) : E257 - E257
  • [28] Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
    Bartlett, Nancy L.
    Costello, Brian A.
    LaPlant, Betsy R.
    Ansell, Stephen M.
    Kuruvilla, John G.
    Reeder, Craig B.
    Thye, Lim S.
    Anderson, Daniel M.
    Krysiak, Kilannin
    Ramirez, Cody
    Qi, Jing
    Siegel, Barry A.
    Griffith, Malachi
    Griffith, Obi L.
    Gomez, Felicia
    Fehniger, Todd A.
    [J]. BLOOD, 2018, 131 (02) : 182 - 190
  • [29] Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
    Michael Wang
    Simon Rule
    Pier Luigi Zinzani
    Andre Goy
    Olivier Casasnovas
    Stephen D. Smith
    Gandhi Damaj
    Jeanette K. Doorduijn
    Thierry Lamy
    Franck Morschhauser
    Carlos Panizo
    Bijal Shah
    Andrew Davies
    Richard Eek
    Jehan Dupuis
    Eric Jacobsen
    Arnon P. Kater
    Steven Le Gouill
    Lucie Oberic
    Tadeusz Robak
    Preetesh Jain
    Melanie M. Frigault
    Raquel Izumi
    Dorothy Nguyen
    Priti Patel
    Ming Yin
    Monika Długosz-Danecka
    [J]. Leukemia, 2019, 33 : 2762 - 2766
  • [30] Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Olivier
    Smith, Stephen D.
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Le Gouill, Steven
    Oberic, Lucie
    Robak, Tadeusz
    Jain, Preetesh
    Frigault, Melanie M.
    Izumi, Raquel
    Dorothy Nguyen
    Patel, Priti
    Yin, Ming
    Dlugosz-Danecka, Monika
    [J]. LEUKEMIA, 2019, 33 (11) : 2762 - 2766
12345